ArticleNature aging2025
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials.
Abstract read
In one paragraph
Article in Nature aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed.
- Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer's disease.Alzheimer's research & therapy · 2026Trial
- Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.JAMA network open · 2026Trial
- Associations of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Association of tongue, handgrip, and pinch strength with blood-based phosphorylated-tau 181 in cognitively healthy older adults.GeroScience · 2026Article
- Article
- Machine Learning and Multimodal Biomarker Discovery in Alzheimer's Disease.Brain sciences · 2026Review
- MRI-derived periventricular diffusivity contextualizes plasma pTau217 associations with Alzheimer pathology: a discovery-validation study.Research square · 2026Article
- Review
- Comparative Prognostic Performance of Hippocampal Volume and Plasma Biomarkers in Amyloid-Negative Subjective Cognitive Decline: A Four-Year Follow-up.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers.Science advances · 2026Article
- Plasma p-tau217 as a two-cutoff approach to improve tau-PET screening and trial recruitment in Alzheimer's disease.Scientific reports · 2026Article
- Advances in biomarker discovery for canine cognitive dysfunction: a comprehensive structured narrative review and future perspectives.Veterinary research communications · 2026Review
- Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline.JAMA network open · 2026Article
- Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Observational
- Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Group-level versus individualized approaches for capturing tau PET changes and clinical progression in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Prognostic value of plasma %p-tau217 in cognitively unimpaired older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Rik Ossenkoppele *Clinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden. r.ossenkoppele@amsterdamumc.nl.ORCID http://orcid.org/0000-0003-1584-7477
Gemma Salvadó *Clinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-5210-9230
Shorena JanelidzeClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-2869-8378
Alexa Pichet BinetteClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Divya BaliClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Linda KarlssonClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-0630-772X
Sebastian PalmqvistClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-9267-1930
Niklas Mattsson-CarlgrenClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Joseph TherriaultTranslational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Montreal, Quebec, Canada.
Nesrine RahmouniTranslational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Montreal, Quebec, Canada.
Pedro Rosa-NetoTranslational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0001-9116-1376
Emma M CoomansAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Elsmarieke van de GiessenNeurodegeneration, Amsterdam Neuroscience, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-9956-4233
Wiesje M van der FlierAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-8766-6224
Charlotte E TeunissenNeurodegeneration, Amsterdam Neuroscience, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-4061-0837
Erin M JonaitisWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Sterling C JohnsonWisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.ORCID http://orcid.org/0000-0002-8501-545X
Sylvia VilleneuveCentre for Studies on the Prevention of Alzheimer's Disease (StoP-AD), Douglas Mental Health University Institute, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0003-2338-0467
PREVENT-AD Research Group
Tammie L S BenzingerDepartment of Radiology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-8114-0552
Suzanne E SchindlerCharles F. and Joanne Knight Alzheimer Disease Research Center, Washington, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-1680-1465
Randall J BatemanCharles F. and Joanne Knight Alzheimer Disease Research Center, Washington, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-7729-1702
James D DoeckeAustralian eHealth Research Centre, Commonwealth Scientific and Industrial Research Organization, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2863-0293
Vincent DoréAustralian eHealth Research Centre, Commonwealth Scientific and Industrial Research Organization, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8051-0558
Azadeh FeizpourDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.ORCID http://orcid.org/0000-0003-0826-4011
Colin L MastersThe Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Parkville, Victoria, Australia.
Christopher RoweDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.ORCID http://orcid.org/0000-0003-3910-2453
Heather J WisteDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8178-6601
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7916-622X
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden. oskar.hansson@med.lu.se.ORCID http://orcid.org/0000-0001-8467-7286
Funding
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI Tammie Lee Smith Benzinger · 1985 to 2026
$69.5MSUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5MWisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7MThe Longitudinal Course of Neural Function and Amyloid in People At Risk for ADR01AG021155 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sterling C Johnson · 2004 to 2026
$27.0MBlood amyloid, tau, and neurodegeneration biomarkers and prediction of clinical onset, cognitive decline, and dementia diagnosisR01AG061900 · NIA · WASHINGTON UNIVERSITY · PI RANDALL J BATEMAN · 2024 to 2026
$16.8MBlood amyloid-beta relationship with amyloid plaques and CSF amyloid-betaRF1AG061900 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2019 to 2020
$6.9MDisease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8MStaging Alzheimer disease with blood-based biomarkersR01AG070941 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2021 to 2025
$4.3MProspective validation and implementation of high-performing blood biomarkers and digital cognitive tests for detection of Alzheimer's disease in specialist memory clinic and primary care settingsR01AG083740 · NIA · LUNDS UNIVERSITET · PI Sebastian Palmqvist · 2023 to 2026
$1.9MBlood amyloid-beta relationship with amyloid plaques and CSF amyloid-betaR56AG061900 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2018 to 2018
$1.4MNIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS R01 AG021155NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG061900NIA NIH HHS R01 AG070941NIA NIH HHS R01 AG083740NIA NIH HHS R37 AG011378NIA NIH HHS R56 AG061900NIA NIH HHS RF1 AG061900NIA NIH HHS U01 AG006786
Abstract
Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer's disease (AD), but their relative performance in predicting future cognitive decline among cognitively unimpaired (CU) individuals is unclear. In a head-to-head comparison study including nine cohorts and 1,474 individuals, we show that plasma p-tau217 and medial temporal lobe tau-PET signal display similar associations with cognitive decline on a global cognitive composite test (R
Indexed as
CognitionCognitive DysfunctionPositron-Emission Tomographytau ProteinsAgedAged, 80 and overAlzheimer DiseaseBiomarkersClinical Trials as TopicDisease ProgressionFemaleHumansMaleMiddle AgedPhosphorylationBiomarkersMAPT protein, humantau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.